HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | MicrobiomeTrials← Back to trialsNCT07811986
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-01Est. Completion: 2027-12-31
Enrollment target: 20 participants Locations- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, 300000, Tianjin, China
Other microbiome trials you might be interested in
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United StatesCompleted Jan 1, 2033
Blood CancersLeukemiaLymphomaBone Marrow TransplantPsychological TraumaNeoplasmsHematological MalignanciesHematological Cancers
Hematological Neoplasm
Lymphoma Non-Hodgkin
Lymphoma Diffuse Large B-cell
Leukemia Acute Myeloid - AML
Chronic Myeloid Leukemia (CML)
Acute Lymphoid Leukemia (ALL)
Myelodysplastic Syndrome
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help the…
Thessaloniki, GreeceEst. completion Dec 31, 2026